Results were very similar after reclassification of cases according to ICC22, except for two cases: one AML-NOS by WHO17 that was relocated to AML with TP53 mutation (AML-TP53m) and another case with MDS history AML-MR that did not show any MR-genetic alteration (further described below). This evidence concerns the gene TP53 and acute myeloid leukemia.